In the in vitro model, CLL cells were treated with two SYK inhibitors: cerdulatinib (a dual inhibitor of SYK/JAK (PRT062070) and the highly specific SYK inhibitor PRT060318) and dasatinib (a LYN and BTK inhibitor). Here, SYK is linked to B-cell chronic lymphocytic leukemia.